

1 September 2025

Osteopore advances into cellular regenerative medicine via AUD 0.5m strategic investment

Highlights

- OsteoRx, a special purpose vehicle (“SPV”), focusing on integrating biotech and medtech to drive breakthroughs in tissue regeneration, diseases cures, and the promotion of geroscience and longevity, has been established following the completion of due diligence and necessary approvals.
- Osteopore will invest an initial tranche of AUD 0.5m to catalyse operations and platform development.
- Subject to conditions precedent, a controlling stake in RxCell Inc, a leading iPSC company, will be injected into OsteoRx resulting in renowned scientists Dr Xianmin Zeng and Dr Brian Kennedy being co-owners in the SPV.
- This strategic move reinforces Osteopore’s leadership in regenerative medicine while expanding its reach across upstream biotech and medtech.
- The investment also deepens Osteopore’s exposure to the USD 19.34b stem cell market, projected to reach USD 55.75b by 2032, at a CAGR of 16.3%¹.

Australian-Singaporean regenerative medicine company **Osteopore Limited (ASX: OSX; Osteopore or the Company)**, a global leader in 3D-printed biomimetic and bioresorbable implants, is pleased to announce the launch of OsteoRx, a bold new special purpose vehicle (SPV) strategically focused on cellular regeneration, geroscience and longevity science. The establishment of OsteoRx follows the completion of due diligence and all necessary approvals. Subject to conditions precedent, a controlling stake in US-based leading-edge induced pluripotent stem cell (iPSC) company RxCell Inc (RxCell) will be injected into the SPV via in-kind contribution by Dr Zeng and Dr Kennedy.

¹ <https://www.fortunebusinessinsights.com/stem-cells-market-105138>

OsteoRx² will be led by Osteopore and renowned scientists Dr Xianmin Zeng and Dr Brian Kennedy, who are internationally recognised for their expertise in stem cell biology, aging biology and translational medicine. Leveraging on Dr Zeng and Dr Kennedy's expertise, the SPV will focus on accelerating breakthrough innovations that address unmet needs in age-related degeneration, chronic disease and tissue regeneration.

Dr Xianmin Zeng, who is an iPSC pioneer and RxCell President and CEO, focuses her research on neural development using iPSC to model neurodegenerative diseases. Dr Zeng was highlighted by the California Institute for Regenerative Medicine (CIRM) for her research into stem cells during her tenure as Professor at the Buck Institute for Research on Aging³.

Dr Brian Kennedy currently holds the position of Distinguished Professor of Biochemistry & Physiology at Yong Loo Lin School of Medicine, National University of Singapore (NUS). He is also the Director of the Centre for Healthy Longevity at the National University Health System (NUHS). Prior to his appointments in NUS and NUHS, Dr Kennedy was the President and CEO of the Buck Institute for Research on Aging, based in Novato, California. Dr Kennedy earned his PhD in Biology from Massachusetts Institute of Technology (MIT), where he took part in groundbreaking studies in aging⁴.

Osteopore shall provide an initial investment of AUD 0.5m to support OsteoRx's early-stage development, research, and operations, with a focus on evolving cutting-edge science into commercially viable therapies that can transform healthspan and quality-of-life.

Beyond the investment, Osteopore contributes clinical, regulatory, and commercialisation experience to help unlock OsteoRx's ambitions across cellular therapies, aging science, and regenerative healthcare.

² ASX announcement, "OSX partners scientists to drive regeneration innovation", 4 November 2024.

³ <https://www.cirm.ca.gov/our-progress/video/parkinsons-ask-stem-cell-expert-xianmin-zeng-buck-institute/>

⁴ <https://web.archive.org/web/20140701154403/http://www.buckinstitute.org/kennedyLab>



Through OsteoRx, Osteopore will have access to IP, technology, and capabilities that enable the Company to expand its reach into the USD 4.39b⁵ (by 2034) scaffold-based cell therapy market, building on the collaboration with RxCell in October 2024⁶.

The establishment of OsteoRx and injection of RxCell deepens Osteopore's exposure to the USD 19.34b stem cell market, projected to reach USD 55.75b by 2032, at a CAGR of 16.3%. This move also reinforces Osteopore's leadership in regenerative medicine.

Osteopore will continue to keep the market updated on key milestone.

Commenting on the Company's strategic expansion in regenerative medicine, Osteopore Chairman Mark Leong said:

"With OsteoRx now established, having made our first investment, we are excited to be part of a transformative journey, sitting at the nexus of biotech and medtech. This move accelerates Osteopore's leadership in regenerative medicine, with meaningful innovations across regeneration and rejuvenation," said Mr Leong.

Commenting on value creation, Osteopore CEO Dr Yujing Lim said:

"This is a pivotal step forward. We are building on our technology leadership position through world-class collaborators, and are now equipped with transformative IP and technology that unlocks the potential to advance novel therapies to address unmet clinical needs," said Dr Lim.

Commenting on the blending of Osteopore and RxCell's capabilities and expertise, Dr Xianmin Zeng said:

"This first investment marks a significant step in our vision to integrate RxCell's iPSC expertise with Osteopore's proven scaffold platform. We're laying the groundwork to accelerate regenerative therapies that can restore function and quality of life, not just treat symptoms," said Dr Zeng.

⁵ <https://www.precedenceresearch.com/scaffold-technology-market>

⁶ ASX announcement, "Osteopore strikes scaffold-based iPSC deal with RxCell", 10 October 2024.

Commenting on how the investment will push the boundaries of cellular regeneration, geroscience and longevity science, Dr Brian Kennedy said:

"This is a powerful development – merging leading-edge biological innovation and engineering excellence. Through capital and strategic alignment, we are well-positioned to push the boundaries of longevity science and advance therapies that enhance healthspan," said Dr Kennedy.

This announcement has been authorised for release by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Mark Leong

Executive Chairman

Osteopore Limited

E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or



representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement.

The forward-looking statements in this announcement reflect views held only as of the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor a tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their advice before making any investment decision.



For personal use only